Recent updates on Amgen (AMGN) show a variety of financial trends and data. The biopharmaceutical company is set to declare a Q3 2025 dividend payout of US$2.38. Numerous stakeholders such as US Bancorp DE, Moors & Cabot Inc., and Commerce Bank, have sold parts of their Amgen stakes. Despite this, institutions like XTX Topco Ltd, Arkadios Wealth Advisors, and Purkiss Capital Advisors LLC have increased their holdings.
The Golden Cross signal flashed on Amgen's chart points towards a potential rise. Market observers are anticipating earnings growth with Q2 report expected to be announced by CEO Bradway on August 5. Amgen is also in the eye of various stock analysts, with UBS keeping a neutral rating but raising its price target from $315 to $326, while BofA reiterates a sell rating.
With Amgen's strong dividend performance, it is considered a standout pick amongst 'Dogs of the Dow'. The company though suffered stock declines after mixed MariTide data from the ADA conference and fierce competition from Novo Nordisk's weight loss drug. However, the market remains positive about Amgen, with the expectation it will maintain its earnings surprise streak.
Positive results from the Phase 3 study of Bemarituzumab and the announcement of full results from part 1 of the Phase 2 study of MariTide are also of note.
Amgen AMGN News Analytics from Mon, 24 Mar 2025 07:00:00 GMT to Sat, 02 Aug 2025 17:19:11 GMT - Rating 6 - Innovation 2 - Information 7 - Rumor -3
